Advanced search
Publication Cover
Acta Oncologica Volume 52, 2013 - Issue 6
Journal homepage
2,231
Views
34
CrossRef citations to date
0
Altmetric
Original Articles

Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients

Samir KapadiaDivision of Hematology and Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA
,
Sanjaykumar HapaniDivision of Hematology and Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA
,
Toni K. ChoueiriKidney Cancer Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
&
Shenhong WuDivision of Hematology and Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USACorrespondence[email protected]
Pages 1202-1212 | Received 28 Sep 2012, Accepted 21 Feb 2013, Published online: 18 Apr 2013

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Haochen Jiang, Ying Jin, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He & Peihua Luo. (2021) Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opinion on Drug Safety 20:3, pages 335-348.
Read now
Florence E Chamberlain, Chris Wilding, Robin L Jones & Paul Huang. (2019) Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opinion on Investigational Drugs 28:6, pages 505-511.
Read now
Vicky L. M. N. Soomers, Ingrid M. E. Desar, Nielka P. van Erp, Jeroen Verwiel, Suzanne E. J. Kaal & Winette T. A. van der Graaf. (2017) Fatal heart failure in a young adult female sarcoma patient treated with pazopanib. Acta Oncologica 56:9, pages 1233-1234.
Read now
Simone Ferrero, Umberto Leone Roberti Maggiore, Nicoletta Aiello, Fabio Barra, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi & Domenica Lorusso. (2017) Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. Expert Opinion on Drug Metabolism & Toxicology 13:8, pages 881-889.
Read now
Qing Ma, Li-Yan Gu, Yao-Yao Ren, Li-Li Zeng, Ting Gong & Dian-Sheng Zhong. (2015) Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. OncoTargets and Therapy 8, pages 2361-2374.
Read now
Rick L. M. Haas, Hans Gelderblom, Stefan Sleijfer, Hester H. van Boven, Astrid Scholten, Luc Dewit, Gerben Borst, Jos van der Hage, J. Martijn Kerst, Remi A. Nout, Henk H. Hartgrink, Ilse de Pree, Cornelis Verhoef, Neeltje Steeghs & Frits van Coevorden. (2015) A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncologica 54:8, pages 1195-1201.
Read now
Myrella Vlenterie, Nielka P. van Erp & Winette T. A. van der Graaf. (2015) Promising management of pazopanib-induced liver toxicity. Acta Oncologica 54:7, pages 1064-1066.
Read now

Articles from other publishers (27)

Hana Studentova, Jindriska Volakova, Martina Spisarova, Anezka Zemankova, Kvetoslava Aiglova, Tomas Szotkowski & Bohuslav Melichar. (2022) Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature. BMC Gastroenterology 22:1.
Crossref
Aurelio A. Moya-García, Andrés González-Jiménez, Fernando Moreno, Camilla Stephens, María Isabel Lucena & Juan A. G. Ranea. (2022) Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury through Systems Pharmacology. Genes 13:7, pages 1292.
Crossref
Yichen Wang & Yoon-Young Jang. 2022. iPSCs - State of the Science. iPSCs - State of the Science 95 109 .
Juul M J Coumans, Anke Oenema, Catherine A W Bolman & Lilian Lechner. (2021) Use and Appreciation of a Web-Based, Computer-Tailored Diet and Physical Activity Intervention Based on the Self-determination Theory: Evaluation Study of Process and Predictors. JMIR Formative Research 5:12, pages e22390.
Crossref
Jin-Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim & Susie Chin. (2021) Pazopanib-induced severe acute liver injury. Medicine 100:46, pages e27731.
Crossref
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter & Cosmin Sebastian Voican. (2021) Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 157, pages 103127.
Crossref
Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albiges, Rachel H. Giles & Eric Jonasch. (2020) Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer 123:6, pages 898-904.
Crossref
Yukinori Harada, Shintaro Kakimoto & Taro Shimizu. (2020) Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma. BMJ Case Reports 13:7, pages e235177.
Crossref
Yi Long Toh, Yi Yun Pang, Maung Shwe, Ravindran Kanesvaran, Chee Keong Toh, Alexandre Chan & Han Kiat Ho. (2020) HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. Heliyon 6:4, pages e03813.
Crossref
Jakob N. Henriksen, Pernille Bøttger, Carina K. Hermansen, Søren A. Ladefoged, Peter H. Nissen, Stephen Hamilton-Dutoit, Thomas L. Fink & Frede Donskov. (2020) Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Clinical Genitourinary Cancer 18:1, pages 62-68.e2.
Crossref
Viktor Grünwald, Martin H. Voss, Brain I. Rini, Thomas Powles, Laurence Albiges, Rachel H. Giles & Eric  Jonasch. (2020) Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. Kompass Onkologie 7:4, pages 180-189.
Crossref
Kazuki Okubo, Akio Horiguchi, Keiichi Ito & Tomohiko Asano. (2018) Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction. Urology Case Reports 20, pages 22-24.
Crossref
Ana Ezponda, Ignacio Gonz�lez De La Huebra, Marta Calvo, Miguel Idoate & Isabel Vivas. (2018) Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report. Oncology Letters.
Crossref
Marie-Noëlle Paludetto, Florent Puisset, Félicien Le Louedec, Ben Allal, Thierry Lafont, Etienne Chatelut & Cécile Arellano. (2018) Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 154, pages 373-383.
Crossref
Bing Liu, Maoxi Yuan, Yi Sun, Ziming Cheng, Zaiyong Zhang, Shizheng Hou, Xiangdong Wang & Jingfeng Liu. (2017) Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget 9:10, pages 9480-9488.
Crossref
Waleed Elsayed Ahmed Ellawatty, Yusuke Masuo, Ken-ichi Fujita, Erina Yamazaki, Hiroo Ishida, Hiroshi Arakawa, Noritaka Nakamichi, Ramadan Abdelwahed, Yasutsuna Sasaki & Yukio Kato. (2018) Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib. Drug Metabolism and Disposition 46:1, pages 33-40.
Crossref
Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria & Bernard Escudier. (2017) Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer 17:1.
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
Nelia Hernandez. (2017) Hepatotoxicity of New Antitumor Agents. Current Hepatology Reports 16:4, pages 293-297.
Crossref
Hesham Elhalawani, Muhammad Heiba & Omar Abdel-Rahman. (2017) Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. Clinical Genitourinary Cancer 15:3, pages e325-e335.
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Yukti Choudhury, Yi Chin Toh, Jiangwa Xing, Yinghua Qu, Jonathan Poh, Huan Li, Hui Shan Tan, Ravindran Kanesvaran, Hanry Yu & Min-Han Tan. (2017) Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Scientific Reports 7:1.
Crossref
Kai Qu, Tian Liu, Ting Lin, Xing Zhang, Ruixia Cui, Sinan Liu, Fandi Meng, Jingyao Zhang, Minghui Tai, Yong Wan & Chang Liu. (2016) Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?. Oncotarget 7:41, pages 67650-67660.
Crossref
Sumitra Shantakumar, Beth L. Nordstrom, Luc Djousse, Susan A. Hall, David R. Gagnon, Kathy H. Fraeman, Myrthe van Herk-Sukel, Karen Chagin & Jeanenne Nelson. (2016) Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer Chemotherapy and Pharmacology 78:3, pages 559-566.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 537 .
Alexander Kornienko, Antonio Evidente, Maurizio Vurro, Véronique Mathieu, Alessio Cimmino, Marco Evidente, Willem A. L. van Otterlo, Ramesh Dasari, Florence Lefranc & Robert Kiss. (2015) Toward a Cancer Drug of Fungal Origin. Medicinal Research Reviews 35:5, pages 937-967.
Crossref
Prinesh N. Patel, Pradipbhai D. Kalariya, Mahesh Sharma, Prabha Garg, M. V. N Kumar Talluri, S. Gananadhamu & R. Srinivas. (2015) Characterization of forced degradation products of pazopanib hydrochloride by UHPLC‐Q‐TOF/MS and in silico toxicity prediction . Journal of Mass Spectrometry 50:7, pages 918-928.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.